Status:
COMPLETED
Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)
Lead Sponsor:
Alcon Research
Conditions:
Glaucoma
Ocular Hypertension
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
The purpose of this study was to assess efficacy and tolerability of travoprost 0.004% vs. bimatoprost 0.01% during the after office hour period (4 pm to 8 pm) in subjects with open-angle glaucoma or ...
Eligibility Criteria
Inclusion
- Clinical diagnosis of open-angle glaucoma (OAG) or ocular hypertension (OHT) in at least one eye.
- Non-study eye: Intraocular pressure (IOP) able to be controlled with no pharmacologic therapy or on the study medicine alone.
- Willing to discontinue the use of all other ocular hypotensive medications prior to receiving study medication and for the entire course of the study.
- Able to follow instructions, self instill study article, and attend all study visits.
- Best-corrected Snellen visual acuity of 20/200 or better in each eye.
- Sign Ethics Committee reviewed and approved informed consent form.
- Other protocol-defined inclusion criteria may apply.
Exclusion
- Known medical history of allergy, hypersensitivity or poor tolerance to any component of the preparations used in this study.
- Any abnormality preventing applanation tonometry in either eye.
- Dry eye previously or currently being treated with punctal plugs, punctal cautery, Restasis®, or topical ocular corticosteroids.
- Concurrent infectious/noninfectious conjunctivitis, keratitis or uveitis in either eye.
- Intraocular conventional or laser surgery \>3 months prior to consent.
- Risk of visual field or visual acuity worsening as a consequence of participation in the study, in the investigator's best judgment.
- Progressive retinal or optic nerve disease from any cause.
- Use of any systemic medications known to affect IOP which have not been on a stable course for at least 7 days prior to Screening or an anticipated change in dosage during the course of the study.
- Any clinically significant, serious, or severe medical condition.
- Women of childbearing potential who are pregnant, lactating, or not using reliable means of birth control.
- Participation in any other study within 30 days prior to Screening.
- Use of any systemic (oral), injectable or topical steroids.
- Other protocol-defined exclusion criteria may apply.
Key Trial Info
Start Date :
October 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
June 1 2012
Estimated Enrollment :
84 Patients enrolled
Trial Details
Trial ID
NCT01464424
Start Date
October 1 2011
End Date
June 1 2012
Last Update
September 13 2013
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.